Efficacy and safety of low dose sirolimus in lymphangioleiomyomatosis
Not Applicable
Recruiting
- Conditions
- lymphangioleiomyomatosis
- Registration Number
- JPRN-UMIN000016677
- Lead Sponsor
- ational Hospital Organization Kinki-chuo Chest Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
1) Pregnancy or planning of pregnancy or lactating 2) Severe dysemia or impairment of liver function 3) Active infection 4) Operation within 8 weeks 5) Severe dyslipidemia 6) Active registration of lung transplantation 7) Allergy of sirolimus
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1) The FEV1 response, which is assessed as the rate of change in FEV1 or the SGRQ score response. 2) Adverse events in sirolimus 1mg/day and 2mg/day.
- Secondary Outcome Measures
Name Time Method